Our Pipeline

AUR-101, RORgt inverse agonist

Stage – Clinical Phase 2B

AUR-101 is an oral, small molecule RORgt inverse agonist. It is the most advanced clinical asset in this class, being developed for the treatment of moderate to severe psoriasis.

CA-170, Dual inhibitor of PDL1 and VISTA

Stage – Clinical Phase 3

CA-170 is an oral, small molecule dual inhibitor of PDL1 and VISTA. In contrast to antibodies, CA-170 offers the advantages of ease of dosing, the ability to manage immune-related adverse events (irAEs), and lower COGs.

AUR-103, CD47 antagonist

Stage – Clinical Phase 1

AU-103 is a highly differentiated oral small molecule inhibitor of CD47. In pre-clinical studies, AUR-103 does not show hemotoxicity. This is in contrast to anti-CD47 antibodies, where significant dose-limiting toxicities of anemia, thrombocytopenia, and leukopenia have been observed.

AUR104           FABP5 inhibitor

AUR-105, PRMT5 inhibitor

Stage – Clinical Phase 1

A substrate competitive inhibitor of PRMT5, with a high tumor/plasma ratio in xenograft studies. AU-105 has demonstrated significant efficacy in multiple pre-clinical cancer models.

AUR-106, Dual inhibitor of TIGIT and PDL1

Stage – Clinical Phase 1

An oral, small molecule inhibitor of TIGIT and PDL1, developed from Aurigene’s small molecule IO platform. In contrast to antibodies, AUR-106 offers the advantages of ease of combination dosing, the ability to manage immune-related adverse events (irAEs), and lower COGs.

AUR-107, CBP/p300 inhibitor

Stage – IND-enabling

AUR-107 is an oral, dual inhibitor of CBP and p300 with excellent selectivity against other bromodomain containing proteins. The molecule has demonstrated excellent efficacy in pre-clinical models with good therapeutic margins.

AUR-108, DHODH inhibitor

Stage – Clinical Phase 1

AUR-108 (formerly known as AG-636) is an oral, potent DHODH inhibitor with high selectivity against a panel of dehydrogenases. It has broad activity in pre-clinical models of lymphoma and leukemia, with a potential for combination with standard of care.

AUR-109, Spectrum selective kinase inhibitor

Stage – Clinical Phase 2A

AUR-109 (formerly known as ODM-203) is an oral, spectrum selective kinase inhibitor targeting DDR1 and SIK2 along with clinically validated targets FGFRs and VEGFRs. It is currently being evaluated in FGFR mutant bladder cancer. The unique selectivity profile allows potential expansion of indications.